Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection (vol 14, pg 4819, 2021)

被引：0
|
作者：
LeVee, A.
Lin, C. Y.
Posadas, E.
机构：
来源：
ONCOTARGETS AND THERAPY | 2021年 / 14卷
关键词：
D O I：
10.2147/OTT.S343977
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：5167 / 5167
页数：1
相关论文
共 50 条
  • [41] Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer (vol 5, pg 117, 2011)
    Paller, C. J.
    Antonarakis, E. S.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 : 183 - 183
  • [42] Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends( vol 42 , pg 631 2022)
    Figueiredo, Arnaldo
    Costa, Luis
    Mauricio, Maria Joaquina
    Figueira, Luis
    Ramos, Rodrigo
    Martins-da-Silva, Carlos
    CLINICAL DRUG INVESTIGATION, 2023, 43 (02) : 153 - 154
  • [43] Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends (vol 42, pg 631, 2022)
    Figueiredo, Arnaldo
    Costa, Luis
    Mauricio, Maria Joaquina
    Figueira, Luis
    Ramos, Rodrigo
    Martins-da-Silva, Carlos
    CLINICAL DRUG INVESTIGATION, 2022, 42 (11) : 1019 - 1020
  • [44] Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Warli, Syah Mirsya
    Velaro, Adrian Joshua
    Firsty, Naufal Nandita
    Tala, Zaimah Zulkarnaini
    WORLD JOURNAL OF ONCOLOGY, 2023, 14 (06) : 518 - 528
  • [45] Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
    Mukherji, Deborah
    Omlin, Aurelius
    Pezaro, Carmel
    Shamseddine, Ali
    de Bono, Johann
    CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) : 555 - 566
  • [46] Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
    Deborah Mukherji
    Aurelius Omlin
    Carmel Pezaro
    Ali Shamseddine
    Johann de Bono
    Cancer and Metastasis Reviews, 2014, 33 : 555 - 566
  • [47] Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer
    Feinman, Hannah E.
    Price, Douglas K.
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2017, 18 (04) : 203 - 204
  • [48] FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
    Fallah, Jaleh
    Xu, Jianjin
    Weinstock, Chana
    Brave, Michael H.
    Bloomquist, Erik
    Fiero, Mallorie H.
    Schaefer, Timothy
    Pathak, Anand
    Abukhdeir, Abdelrahmman
    Bhatnagar, Vishal
    Chiu, Haw-Jyh
    Ricks, Tiffany
    John, Christy
    Hamed, Salaheldin
    Lee, Christal
    Pierce, William F.
    Kalavar, Shyam
    Philip, Reena
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Pazdur, Richard
    Kluetz, Paul G.
    Suzman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (05) : 605 - 613
  • [49] Patient preferences for the treatment of metastatic castration-resistant prostate cancer in Australia (mCRPC): A discrete choice experiment
    Winnall, Wendy R.
    Winkler, Karen
    Godsell, Jenni
    Axford, Laurie
    Xhilaga, Miranda
    Fifer, Simon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 212 - 212
  • [50] Radio-223 treatment in a patient with castration-resistant prostate cancer: clinical case presentation
    Camacho Limas, Christian Patricio
    Gerson Cwilich, Raquel
    Villalobos Prieto, Alberto
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 22 - 25
12345